Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

47.18
+0.30000.64%
Post-market: 47.17-0.0100-0.02%19:54 EDT
Volume:10.69M
Turnover:503.24M
Market Cap:96.03B
PE:18.98
High:47.36
Open:46.99
Low:46.82
Close:46.88
52wk High:63.33
52wk Low:42.96
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.05
T/O Rate:0.53%
Dividend:2.46
Dividend Rate:5.21%
EPS(TTM):2.49
EPS(LYR):-4.4144
ROE:29.32%
ROA:8.34%
PB:5.51
PE(LYR):-10.69

Loading ...

BRIEF-Bristol Myers Squibb - Announces Departure Of CMO Samit Hirawat - SEC Filing

Reuters
·
Jul 26

Bristol-Myers Squibb Appoints New Chief Medical Officer

TIPRANKS
·
Jul 26

Bristol Myers Squibb Co - Announces Departure of Cmo Samit Hirawat - SEC Filing

THOMSON REUTERS
·
Jul 26

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Jul 26

Bristol-Myers Squibb’s Promising Phase 3 Study on KarXT for Bipolar-I Disorder

TIPRANKS
·
Jul 26

Bristol-Myers Squibb’s Phase 3 Lung Cancer Study: A Potential Game-Changer?

TIPRANKS
·
Jul 26

Bristol Myers Names Massacesi Chief Medical Officer as Hirawat Departs

Dow Jones
·
Jul 25

BRIEF-Cristian Massacesi, M.D., Joins Bristol Myers Squibb As Executive Vice President, Chief Medical Officer And Head Of Development

Reuters
·
Jul 25

Cristian Massacesi, M.d., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

THOMSON REUTERS
·
Jul 25

Trust healthcare analyst holds analyst/industry conference call

TIPRANKS
·
Jul 24

Hold Rating on Bristol-Myers Squibb Amid Awaited Clinical Trial Outcomes and Mixed Market Signals

TIPRANKS
·
Jul 24

Bausch Health Companies Appoints Michael Goettler and Sandra Leung to Board of Directors, Expanding Leadership Team

Reuters
·
Jul 24

Roche considering selling drugs directly to US patients, CEO says

Reuters
·
Jul 24

Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer for Bipolar-I Disorder

TIPRANKS
·
Jul 24

Dr Reddy's kicks off India big pharma earnings with narrow profit miss

Reuters
·
Jul 23

Bristol-Myers Squibb Completes Key Study on Hypertrophic Cardiomyopathy in Japan

TIPRANKS
·
Jul 23

Bristol-Myers Squibb’s Phase 3 Study on Iberdomide: A Potential Game-Changer in Multiple Myeloma Treatment

TIPRANKS
·
Jul 23

BUZZ-Replimune falls over 70% as US FDA declines to approve skin cancer drug

Reuters
·
Jul 22

Bristol Myers Squibb Co. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jul 22

BRIEF-Bristol Myers Squibb’S Supplemental New Drug Application (SNDA) For Sotyktu (Deucravacitinib) Accepted for Review Across Four Regions

Reuters
·
Jul 21